中国临床药理学杂志2016，Vol.32Issue(12)：1091-1093,3.DOI:10.13699/j.cnki.1001-6821.2016.12.011
阿瑞匹坦对恶性肿瘤神经激肽－1受体和 P物质表达的影响
Effect of aprepitant on the expression of substance P and neurokinin -1 receptor in cancer
摘要
Abstract
Objective To study the expression of substance P and its re-ceptor neurokinin -1 receptor ( NK-1 R) in non-small cell lung can-cer(NSCLC) and A549 cells and to explore the effect of NK -1R anta-gonist aprepitant (aprepitant) on the expression of NK -1R and substance P.Methods The expression of substance P and NK -1 R in primary tumor tissues of NSCLC patients , corresponding adjacent tissues and rela-tively normal lung tissues were detected by immunohistochemistry , and expression of substance P and NK -1 R in A549 cells were detected by immunocytochemistry.Effect of aprepitant on the growth and proliferation of A549 cells were detected by MTT.Results Expression of substance P and NK-1 R in NSCLC tissues was significantly higher than that in ad-jacent normal tissue and normal lung tissue , the differences were statisti-cally significant.In NSCLC tissues , positive expression of substance P was mainly located in the cytoplasm of lung cancer cells , and NK-1R was expressed in cytoplasm and membrane.Substance P and NK -1R were expressed in the vast majority of A 549 cells.Substance P and NK-1 R significantly decreased in A 549 cells by the use of aprepitant.The most obviously inhibitory concentration of aprepitant was 1 ×10 -6 mol· L-1.Conclusion The high expression of substance P and NK -1R in NSCLC and A549 cells suggested that neuroendocrine mechanisms was involved in the development and progression of NSCLC .NK-1 receptor inhibitors inhibited the expression of substance P and NK -1 R as well as the growth and proliferation of A 549 cells, NK-1 receptor may become a new target for the treatment of NSCLC.关键词
阿瑞匹坦/P物质/神经激肽-1受体/肺癌Key words
aprepitant/substance P/neurokinin -1 receptor/lung cancer分类
医药卫生引用本文复制引用
石磊,王丽丽..阿瑞匹坦对恶性肿瘤神经激肽－1受体和 P物质表达的影响[J].中国临床药理学杂志,2016,32(12):1091-1093,3.基金项目
浙江省中医药科学研究基金资助项目 （）
